electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript

electroCore NASDAQ: ECOR reported second-quarter 2026 revenue of $9.5 million, up approximately 28%

electroCore, Inc. (ECOR) came out with a quarterly loss of $0.33 per share versus the Zacks Consensu

electroCore (NASDAQ:ECOR) lowers FY2026 sales outlook from $41.642 million to $41.600 million vs $41

electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.33) per share which beat the analyst cons

Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second qu

ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-sta

ROCKAWAY, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-sta

Ecora Royalties PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF, FRA:HGR) reported that its quarterly portfolio

ROCKAWAY, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-sta

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's

Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market

electroCore, Inc. (ECOR) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2

ROCKAWAY, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-sta

RBC Capital Markets has reiterated its 'outperform' rating and 185p price target on Ecora Royalties

ROCKAWAY, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-sta

ROCKAWAY, N. J. , June 02, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-s

electroCore NASDAQ: ECOR Interim President and CFO Joshua Lev said the bioelectronic technology comp

The publication in JAMA Network Open, titled, "Transcutaneous Electrical Nerve Stimulation and P

ROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stag

ROCKAWAY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stag

electroCore, Inc. (ECOR) Q1 2026 Earnings Call Transcript

electroCore, Inc. (ECOR) came out with a quarterly loss of $0.59 per share in line with the Zacks Co

electroCore (NASDAQ:ECOR) affirms FY2026 sales outlook from $41.642 million to $41.642 million vs $4

electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.59) per share which missed the analyst co

First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quar

The publication reports results from a post-hoc analysis of 35 patients with chronic mTBI and PTSD.

U.S. Patent No. 12,208,263, entitled "Devices and Methods for Vagal Nerve Stimulation" was i

electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.34) per share which beat the analyst cons

electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the "Company"), a bioelectronic t

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains electroCore (NASDAQ:ECOR) with a

electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the "Company"), a bioelectronic t

Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9

https://ppubs.uspto.gov/api/pdf/downloadPdf/12469610?requestToken=eyJzdWIiOiIzZTQ5MWI5NS0wZjI4LTQwYj

electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.40) per share which met the analyst conse

electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, to

electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.44) per share which missed the analyst co

electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.47) per share which missed the analyst co